Skip to main content

Table 2 CL-RI of the treatment groups

From: Luteal blood flow in patients undergoing GnRH agonist long protocol

  No. of patients CL-RI No. of patients with CL-RI < 0.51
Control 9 0.546 ± 0.013 2/9
HCG 8 0.475 ± 0.022b 7/8c
Vitamin E 7 0.431 ± 0.015a 7/7c
  1. The table summarizes the data in Figure 1. Corpus luteum-resistance index (CL-RI) was measured during the mid-luteal phase in the control group, HCG group, and vitamin E group. The value shows the mean ± SEM from the patient mean value. In this study, when CL-RI was more than 0.51, the patient was diagnosed as having decreased luteal blood flow.
  2. a; p < 0.01 and b; p < 0.05 v.s. control (Kruskal-Wallis test followed by the Mann-Whitney U-test using the Bonferroni correction). c; p < 0.01 v.s. control (x2-test with Bonferroni correction).